Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor & fibroid embolization cases in Washington: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (118 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 5 | 297 | 37% |
| 2020 | 9 | 342 | 40% |
| 2021 | 9 | 321 | 43% |
| 2022 | 5 | 314 | 46% |
| 2023 | 4 | 272 | 50% |
| 2024 | 8 | 333 | 54% |
| 2025 from claims | – | 391 316–459 | 54% |
| 2026 forecast | – | 412 323–518 | 54% |
| 2027 forecast | – | 430 319–569 | 55% |
| 2028 forecast | – | 449 318–619 | 56% |
| 2029 forecast | – | 468 318–670 | 57% |
| 2030 forecast | – | 487 319–723 | 57% |
Chemo- and radioembolization of liver tumors, uterine fibroid and other organ embolization (one code covers all). Professional codes (what the surgeon bills): CPT 37243.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Washington; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 61% hospital outpatient, 39% office. The share outside the hospital has moved +39 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Office |
|---|---|---|
| 2026 · ~410 | ~230 | ~190 |
| 2027 · ~430 | ~220 | ~210 |
| 2028 · ~450 | ~230 | ~220 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 50% (61% in 2025), office about 50% (39% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 34 | 1,753+3.4%/yr | +3.4%/yr | 0.5 | 40% | 4,240 in 2030+16%/yr |
| Arizona | 11 | 723+24%/yr | +24%/yr | 1.0 | 78% | 1,640 in 2030+15%/yr |
| Colorado | 4 | 415+7.6%/yr | +7.6%/yr | 0.9 | 70% | 820 in 2030+12%/yr |
| Oregon | 6 | 355+8.7%/yr | +8.7%/yr | 0.9 | 30% | 460 in 2030+4.5%/yr |
| Utah | 2 | 100−2.9%/yr | −2.9%/yr | 0.5 | 38% | 190 in 2030+11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 88 | 5,486−3%/yr | −3%/yr | 7.61.2× | 47% | 5,580 in 2030+0.3%/yr |
| Tumor ablation | 0 | 149−4.5%/yr | −4.5%/yr | 0.20.7× | 0% | 40 in 2030−20%/yr |
Tumor & fibroid embolization in every state, and its device makers · Every procedure market in Washington · Every state · Compare with California
Sirtex Medical leads with 63% of company spending on these surgeons in 2025, +22 pts on 2024.
In 2025, 15 companies reported engagement with Washington’s surgeons worth $121K in consulting, speaking, meals and travel tied to these products, about $15K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 16 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.